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Abstract
The 6
th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF6) was held 1-3 June, 2010 in Seoul,
Korea, with 150 participants from 38 countries. The year 2010 marks the midpoint between the first GAELF meet-
ing, in 2000, and the World Health Organization (WHO) 2020 goal of global elimination of lymphatic filariasis (LF) as
a public health problem. The theme of the meeting, “Half-time in LF Elimination: Teaming Up with Neglected Tro-
pical Diseases (NTDs),” reflected significant integration of LF elimination programmes into a comprehensive initia-
tive to control NTDs. Presentations on LF epidemiology, treatment, research, and programmes highlighted both
accomplishments and remaining challenges.
The WHO strategy to interrupt LF transmission is based on annual mass drug administration (MDA) using two-drug
combinations. After mapping the geographic distribution of LF, MDA is implemented for ≥ 5 years, followed by a
period of post-MDA surveillance, and, ultimately, verification of LF elimination. Morbidity management further
reduces disease burden.
Of 81 countries considered LF-endemic in 2000, 52 (64.2%) have begun MDA; 10 (12.3%) others with low-level
transmission are unlikely to require MDA. In 2008, ~695 million people were offered treatment (51.7% of the at-risk
population); ~496 million participated. Approximately 22 million people have been protected from LF infection and
disease, with savings of ~US $24.2 billion. Morbidity management programmes have been implemented in 27
(33.3%) countries.
Significant challenges to LF elimination remain. These include: initiating MDA in the remaining 19 countries that
require it; achieving full geographic coverage in countries where MDA has started; finding alternative strategies to
address the problem of Loa loa co-endemicity in Central Africa; developing strategies to treat urban populations;
initiating and sustaining MDA in settings of armed conflict; developing refined guidelines and procedures for stop-
ping MDA, for post-MDA surveillance, and for verifying the elimination of LF; and integrating morbidity manage-
ment into all LF elimination programmes. Scientific research and enhanced advocacy for NTDs remain critical for
addressing these challenges.
GAELF6 was characterized by enthusiasm and recognition that “teaming up with NTDs” offers opportunities for
new partnerships, fresh perspectives, enhanced advocacy, and greater programmatic integration in a rapidly chan-
ging global health environment.
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The 6
th Meeting of the Global Alliance to Eliminate
Lymphatic Filariasis (GAELF) was held 1-3 June, 2010
in Seoul, Korea. The theme of the meeting, “Half-time
in LF Elimination: Teaming Up with NTDs,” highlighted
the fact that 2010 marks the midpoint between the first
GAELF meeting, held in 2000 in Santiago de Compos-
tela, Spain, and the 2020 World Health Organization
(WHO) goal of global elimination of lymphatic filariasis
(LF) as a public health problem. The “half-time” theme
provided an appropriate backdrop for reflection, assess-
ment, and planning. For many participants, it also coin-
cided with eager anticipation of the World Cup, which
began in South Africa three weeks later.
Given the half-time theme, it was especially fitting that
GAELF6 was held in the Republic of Korea, which in
2008 received official WHO verification that it had
reached its goal of LF elimination. GAELF participants
appreciated the opportunity to learn about the success-
ful effort in Korea. The warm hospitality and seamless
organization of the Korean hosts provided a superb and
relevant setting for this important meeting.
The presentations, by global experts on the epidemiol-
ogy, treatment, research, and programme implementa-
tion of LF, highlighted the impressive accomplishments
of the GAELF’s first 10 years and provided insight into
the major remaining challenges facing the GAELF. Both
accomplishments and challenges were articulated by sev-
eral “case studies” from LF-endemic countries. Formal
and informal discussions were lively and focused. Two
themes, in particular, infused almost every presentation
and discussion. First, LF elimination is increasingly inte-
grated into a larger initiative to control neglected tropical
diseases (NTDs); hence, the theme “Teaming up with
NTDs.” Implications of this “teaming up” will affect all
aspects of the GPELF (Global Programme to Eliminate
Lymphatic Filariasis), including drug regimens, advocacy,
governance, financing, monitoring and evaluation, part-
nerships, morbidity management, vector control,
research, and programme implementation. Secondly, the
global health landscape has undergone remarkable
changes since the GAELF was established, and this has
resulted in new partnerships, initiatives, and funding
opportunities. These changes will only accelerate during
the next 10 years and foresight, flexibility, and strength of
purpose will all be required.
Half-time Assessment
The magnitude of the challenge facing the GAELF in 2000
was staggering. 81 countries were considered endemic for
LF, with 1.34 billion persons at risk of infection and 120
million infected. WHO, as the lead agency in the GPELF,
established two major strategies to achieve the 2020 goal: 1)
stopping the spread of infection through annual mass drug
administration (MDA) using two-drug combinations; and
2) reducing the burden of disease through morbidity man-
agement. WHO recommended a stepwise approach to
interrupt LF transmission, beginning with mapping the dis-
tribution of LF to identify areas in need of MDA, followed
by five or more years of MDA, a period of post-MDA sur-
veillance, and, ultimately, verification of LF elimination.
Despite the challenges, progress toward LF elimination
has been impressive. Of the 81 endemic countries, 10
(12.3%) are unlikely to require MDA based on current
assessment and 52 (64.2%) currently have active MDA
programmes. Of these, 37 countries have completed ≥ 5
rounds of MDA in at least some of their endemic areas.
In 2008, an estimated 496 million people participated in
MDA; 695 million were offered treatment, representing
51.7% of the at-risk population. That same year, the
cumulative number of albendazole tablets donated by
GlaxoSmithKline (GSK) for LF elimination reached 1.4
billion and the number of Mectizan® tablets donated by
Merck & Co., Inc. reached 1.2 billion.
The resulting global impact on health has been enor-
mous. An estimated 22 million people have been pro-
tected from LF infection and disease, with estimated
economic savings of US $24.2 billion. Declines in micro-
filaremia prevalence have been reported from 131 senti-
nel sites after 5 rounds of MDA; 68 (63%) had a 100%
reduction in prevalence. Morbidity management pro-
grammes implemented in 27 (33.3%) of the 81 LF-
endemic countries have shown significant reductions in
acute inflammatory episodes in persons with lymphoe-
dema. An estimated 146 million persons are estimated
to have received “beyond-LF” benefits during the first 8
years of the programme, due to the broad anti-parasitic
activity of the donated drugs.
Challenges for the Next Half
Several significant challenges remain if LF is to be glob-
ally eliminated as a public health problem by 2020. Var-
ious aspects of these challenges were highlighted by
many of the GAELF6 speakers, revealing a strong sense
of consensus on what the challenges are and what may
be needed to meet them. Common themes as to “what
is needed” include even greater advocacy and funding;
carefully targeted operational research, which can readily
be applied in the field; deepened and expanded partner-
ships; persistence; and flexible approaches. Again, all of
this will be taking place within an integrated NTD con-
text and a rapidly changing global health environment.
Key challenges include the following:
Getting started
Nineteen countries that require MDA have not yet
begun. To reach the global goal of 2020, initiating MDA
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priority.
Upscaling
In the countries where MDA has already begun, it is cri-
tical to upscale MDA to full geographic coverage. 70%
of the total at-risk target population, 919.5 million peo-
ple, live in the countries of India, Indonesia, Bangladesh,
Nigeria, and the Democratic Republic of Congo. Full
geographic coverage, which has been achieved by India,
is a priority for the other four countries.
Loa loa
In Central Africa, Loa loa co-endemicity has presented a
major barrier to initiating LF elimination programmes.
Research is underway, and results are urgently needed,
to find and test alternative or provisional strategies.
Urban populations
Strategies must be developed to effectively treat urban
populations where this is needed, particularly in Africa
and Asia.
Conflict and post-conflict settings
Of the 19 countries with active LF transmission that
have not yet begun MDA, 13 have fragile infrastructures
or are in post-conflict situations. Experience has shown
that MDA is possible in such settings, if special precau-
tions and principles are adhered to.
Post-MDA surveillance
An urgent need exists for refined guidelines for stopping
MDA and for post-MDA surveillance.
Verification of elimination
Procedures, guidelines, and criteria for verifying the elim-
ination of LF are needed so that formerly-endemic coun-
tries can be “taken off the list” as they reach their goal.
Morbidity management and disability prevention
Only 27 LF-endemic countries have active morbidity
management and disability prevention programmes.
Morbidity management should be part of all LF elimina-
tion programmes. Integrated NTD case management
offers the promise of new partnerships and broader inte-
gration of LF morbidity management into existing
health services.
Opportunities and Resources
Speakers at GAELF6 highlighted the lessons that have
been learned during the first 10 years of the partnership.
These lessons provide insights, as well as opportunities,
to address the remaining challenges.
GAELF
The open, inclusive nature of the GAELF, with its
“light” governance structure and regional approach, pro-
vides a solid foundation for meeting the 2020 goal and
for leadership within an integrated NTD initiative.
Human resources and goodwill
In addition to the GAELF, the most important resource
for success lies in the strength and dedication of the
many thousands of people involved in LF elimination
across the globe. As Dr Mwele Malecela said in one of
her presentations, “It is your commitment, your passion,
your belief in the possibility of LF elimination that gives
the Alliance its strength.”
Research
Participants at the GAELF6 learned of several major
research initiatives to address obstacles to LF elimina-
tion. Studies are underway on the impact of vector con-
trol on LF transmission; alternative drug regimens and
drug dosing; new macrofilaricidal agents; and assess-
ment of diagnostic tools, including xenomonitoring of
vectors to detect filarial DNA, among others.
Funding and support
In the last few years, significant new funding has been
committed to LF by the UK Department for Interna-
tional Development (DFID), the US Agency for Interna-
tional Development (USAID), and the Bill & Melinda
Gates Foundation. The commitment by GSK and Merck
& Co., Inc. to donate drugs as well as provide other sup-
port remains essential and strong. GAELF6 participants
learned of line-item funding for LF elimination in Min-
istry of Health budgets and of the fund established by
the President of Tanzania for hydrocele surgery. Thanks
in part to the integration of LF with other NTDs, advo-
cacy for funding is more successful than ever before as
in many countries the LF programme establishes the cri-
tical platform.
Integration
As noted above, “teaming up with NTDs” offers many
opportunities for new partnerships, fresh perspectives,
enhanced advocacy, and a greater role for programmatic
aspects that have to date received limited attention (e.g.,
vector control and morbidity management).
Conclusion
The GAELF6 meeting provided a rich opportunity for
150 attendees from 38 countries to take stock, reflect,
celebrate, and plan for the future. A sense of enthusiasm
and celebration infused the meeting, as well as recogni-
tion and anticipation of the challenges ahead. A strong
sense of partnership was palpable, which bodes well for
the next 10 years.
Tuesday, 1 June 2020
Opening Session
Chair: Dr Jong-Koo Lee Deputy Minister/Director, Min-
istry of Health and Welfare, Korea Centers for Disease
Control and Prevention (KCDC)
Dr Young-Hak Yoo, Honourable Deputy Minister of
Health and Welfare of Korea, opened the 6
th meeting of
the Global Alliance to Eliminate Lymphatic Filariasis
(GAELF). He welcomed the 150 participants from 38
countries and expressed appreciation for the opportunity
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of lymphatic filariasis (LF). He voiced hope that the
meeting would strengthen international cooperation in
the global effort to eliminate LF.
Dato Dr Tee Ah Sian, Director of the Division of
Combating Communicable Diseases, Western Pacific
Region (WPR) of the World Health Organization
(WHO), thanked the government of Korea for hosting
the meeting and welcomed the participants. She high-
lighted the substantial physical and psychological bur-
dens of LF and noted progress in developing effective
laboratory tools and public-private partnerships to elimi-
nate LF. Several countries in the WPR appear to be
close to eliminating LF and others have made substan-
tial progress. Dr Tee called upon the GAELF to assist
Papua New Guinea in mobilizing the financial and tech-
nical resources necessary to eliminate LF.
Dr Dirk Engels, Coordinator of Preventive Chemother-
apy & Transmission Control (PCT) at WHO in Geneva,
conveyed greetings from Dr Margaret Chan, WHO
Director-General, and Dr Lorenzo Savioli, Director of
the Department of Control of Neglected Tropical Dis-
eases. He remarked that, in 2008, the Global Programme
to Eliminate Lymphatic Filariasis (GPELF) targeted 695
million people with mass drug administration (MDA)
and treated 496 million [1]. The strength of the GAELF
lies in its members, each with a different mandate, but
all sharing the same goal. Dr Engels reviewed some of
GAELF’s successes and reiterated WHO’s full support.
He emphasized that MDA for LF elimination should be
thoroughly integrated with preventive chemotherapy for
neglected tropical diseases (NTDs). He thanked GlaxoS-
mithKline (GSK) and Merck & Co., Inc. for their contin-
ued commitment to provide antifilarial drugs, free of
charge, for as long as necessary. Dr Engels encouraged
the meeting participants to celebrate the successes
already achieved and noted that the LF elimination pro-
gramme already has been successful in improving the
health of millions of poor people.
On behalf of the delegates to the 6
th GAELF, Professor
David Molyneux, Executive Secretary of the Executive
Group, GAELF, extended his thanks to the Korean hosts
of the meeting and noted the significance of holding the
meeting in a country that has successfully eliminated
LF. Professor Molyneux emphasized the dramatic
changes in the global health agenda during the first 10
years of the GAELF’s history, especially the substantial
funds recently pledged to control and eliminate NTDs.
He stated that LF elimination is at the forefront of NTD
programmes, and that this was made possible by drug
donations from GSK and Merck & Co., Inc.
The first 10 years of the GAELF have demonstrated
that elimination of LF as a public health problem is an
achievable goal, with enormous public health benefits.
Professor Molyneux noted that the GPELF, while main-
taining its LF focus, can serve as a platform for integra-
tion with other NTDs. The features of the GAELF - a
loose, non-restrictive, representative governance struc-
ture, regional approaches, mutual respect, and the ability
to learn lessons and adapt - have made it strong and
attractive to a diverse array of partners.
Dr Mwele Malecela, Acting Director-General, National
Institute for Medical Research, United Republic of Tan-
zania thanked the GAELF members, especially the
Executive Group and the Secretariat, for their support
during her four years as President of GAELF. She
reflected on some of the lessons learned during the past
four years. These lessons include: partnership is a pro-
cess; consensus can emerge from chaos; and advocacy
can move mountains. The flexible nature of GAELF has
allowed its members to forge new partnerships and to
move from strength to strength. She thanked the gov-
ernment of the Republic of Korea and the KCDC for
hosting the meeting and told the participants that, “it is
your commitment, your passion, your belief in the possi-
bility of LF elimination that gives the Alliance its
strength.”
Dr Jong-Koo Lee, Deputy Minister/Director, Ministry
of Health and Welfare, KCDC, thanked the GAELF for
the opportunity to host GAELF6. He noted that, before
LF elimination was verified by WHO in 2008, LF had
been endemic in Korea for millennia. LF was the first
disease to be officially eliminated in Korea. Dr Lee
pledged that during the next decade, global health will
remain high on Korea’s development agenda. He wished
the participants much success and declared the meeting
officially opened.
Keynote Addresses
Chair:P r o f e s s o rJ o n g - Y i lC h a i ,S e o u lN a t i o n a lU n i v e r -
sity College of Medicine
The first session of the conference, chaired by Profes-
sor Jong-Yil Chai, described the successful elimination
of LF in Korea. Professor Han-Jong Rim, Emeritus Pro-
fessor at Korea University College of Medicine, reviewed
the history of LF elimination in Korea, which can be
considered in three distinct phases [2]. During the first
phase, 1920-1945, LF was initially recognized as an
endemic public health problem and was found to be
caused only by Brugia malayi.
The period 1951-1979 was one of investigation and
surveillance. Three major endemic areas were identified:
Jeju Island; the southwest coastal area; and an area in
the southeast, which extended inland. Epidemiologic
investigations were conducted in all of these areas,
where microfilaremia prevalence ranged from 1 to 22%.
These investigations showed that B. malayi was noctur-
nally periodic and the principal vectors were Aedes togoi
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LF transmission was detected in the central part of the
country, which is mountainous. Persons infected with B.
malayi were treated selectively with diethylcarbamazine
(DEC), beginning with low doses to minimize adverse
reactions. Certain aspects of traditional life were identi-
fied as facilitating transmission, including the habit of
gathering water during the evenings, and the thatched
roofs, which provided resting places for A. togoi.
The third phase, from 1980 to 2007, focused on che-
motherapy and control of LF. Dr Rim noted that Korea
did not have a centralized national LF control pro-
gramme. Rather, the Korean National Institute of Health
conducted and coordinated LF control efforts that were
carried out by a variety of investigators. The primary
control measures included epidemiologic investigation
and surveillance along with selective chemotherapy, pri-
marily with DEC. Economic growth and improved living
conditions, which facilitated lifestyle changes, decreased
exposure to mosquitoes. A progressive socio-economic
development plan, known as “Saemaul Undong,” was
launched in 1970. This public works programme
improved housing conditions, did away with traditional
thatched roofs, and decreased mosquito breeding habi-
tat; it also dramatically increased per-capita income. The
prevalence of B. malayi infection declined rapidly, as did
the prevalence of soil-transmitted helminths (STHs),
from 80% in 1969 to nearly zero in 1989 (Figure 1). In
commenting on the relationship between economic
development and parasitic diseases, Dr Rim said that
social and environmental change, made possible by eco-
nomic growth, was primarily responsible for the dra-
matic decline in soil-transmitted diseases and LF in
Korea.
Dr Hyeng-Il Cheun, Research Fellow, Division of
Malaria and Parasitic Diseases, National Institute of
Health, KCDC, gave additional detail on the LF elimina-
tion programme in Korea, focusing on epidemiological
surveys and elimination efforts between 2002 and 2006
[3]. The objectives during this period were to enhance
surveillance in suspected areas; detect infected persons;
provide selective and mass chemotherapy; confirm the
Figure 1 Prevalence of infection with soil-transmitted helminths and per-capita gross national product (GNP), Republic of Korea,
1969-1988.
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elimination. Surveys were repeated on many of the
islands, and previous efforts to reduce transmission were
found to have been effective. For example, in Jeollanam-
do, microfilaremia prevalence was 9.8% in 1986-1992. In
2002, only two persons, both > 60 years old, were found
to be infected, for a prevalence of 0.1%. In other areas
where LF prevalence had been lower in 1992, no one
tested positive in 2002-2004.
In October 2005, a team from WHO visited Korea
and recommended that 3000 elementary school children
and older residents of formerly-endemic areas be tested
with a rapid antibody test for Brugia malayi. All chil-
dren had negative test results. In March 2008, WHO
officially concluded that the Republic of Korea had
achieved the elimination of LF as a public health
problem.
Address by GlaxoSmithKline
Dr Yil-Seob Lee, Medical and Regulatory Director of
GlaxoSmithKline in Korea, gave an overview of GSK’s
humanitarian efforts. To fulfil its commitment to pro-
vide albendazole for LF elimination, GSK opened a new
albendazole manufacturing facility in India in 2009.
Among its other humanitarian programmes, GSK spon-
sors research on diseases endemic in the poorest coun-
tries; re-invests in the least-developed countries 20% of
profits made on medicines sold in those countries; and
shares its laboratory space with independent researchers
working on neglected diseases. Dr Lee emphasized the
importance of partnership and collaboration in achiev-
ing the goal of LF elimination.
Address by Merck Sharpe & Dohme
Mr Key Lee, head of External Affairs, Merck Sharpe &
Dohme (MSD) in Korea, noted both the tremendous
progress made in LF elimination thus far and the mag-
nitude of the work ahead. In 1998, the Mectizan Dona-
tion Program (MDP) was expanded to target LF
elimination in 28 African countries and Yemen, where
onchocerciasis was co-endemic. Last year, > 100 million
doses of Mectizan® were approved for combination ther-
apy against LF. Dr Lee reiterated MSD’s commitment to
provide Mectizan® free of charge, for as long as needed,
both for onchocerciasis control and LF elimination. He
urged the GAELF participants not to forget those who
suffer from filarial disease. Dr Lee called for continued
momentum through strengthened partnerships to
address NTDs, and briefly highlighted MSD’so t h e r
humanitarian programmes in Korea.
First Half: The Journey from Santiago de Compostela to
Seoul
Chair: Dr Mwele Malecela
The Alliance Journey: The Changing Environment and
Adapting the Game Plan
Professor David Molyneux, Senior Professorial Fellow,
Centre for Neglected Tropical Diseases, Liverpool School
of Tropical Medicine, reflected on how dramatically the
international health environment has changed since the
first GAELF meeting in Santiago de Compostela in 2000.
Some of these milestones include the release of the
Report of the Commission on Macroeconomics and
Health, chaired by Dr Jeffrey Sachs; the adoption of the
Millennium Development Goals (MDGs); the establish-
ment of the Global Fund for AIDS, Tuberculosis, and
Malaria; the emergence of numerous public/private part-
nerships; funding support from the Bill & Melinda Gates
Foundation for international health research; the emer-
gence of the “NTD brand” following seminal meetings in
Berlin; and increased references to NTDs by the Direc-
tor-General of WHO and national leaders in Europe and
North America.
Professor Molyneux described “major routes” on the
journey of the GAELF. These have included a global
commitment to LF elimination; a strong research
agenda, with support from numerous public and private
institutions; and enhanced advocacy for NTDs.
The GAELF also has travelled extensively on “country
roads,” which include years of commitment to LF con-
trol before 1997 by the governments of China, Korea,
India, Thailand, Sri Lanka, and Suriname amongst
others; a unified embrace of WHO’s strategy for LF;
successful efforts to “scale up” programmes to the
national level in many countries; and the substantial
financial contributions to LF elimination made by filaria-
sis-endemic countries themselves.
Professor Molyneux outlined several “roadblocks” to
global LF elimination, including Loa loa in West Africa;
challenges to upscaling programmes in countries where
the greatest LF burden remains; conflict and post-con-
flict situations in several countries; supply and financing
of DEC; and morbidity control. He concluded with the
phrase, “Many roads - one journey - same destination:
LF elimination.”
Goals Scored: Progress Achieved in LF Elimination
Dr Kazuyo Ichimori, WHO Focal Point for Lymphatic
Filariasis Elimination, reviewed the key milestones in
GPELF’s 10-year history and provided an assessment of
its impact and the major remaining challenges. The data
that she presented represented official WHO statistics
as of May 2010.
The GPELF had its origins following the World
Health Assembly (WHA) resolution 50.29, passed in
1997, which urged member states to eliminate LF as a
public health problem. WHO published a strategic plan
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held its first meeting in 2000 in Santiago de Compostela,
Spain. WHO is currently preparing a report that will
review progress from 2000 to 2009 and lay out a strate-
gic plan for LF elimination for 2010-2020.
The GPELF set as its goal the global elimination of LF
as a public health problem by 2020, to be achieved
through two major strategies: 1) stopping the spread of
infection by using MDA; and 2) reducing the burden of
disease through morbidity management. A stepwise pro-
grammatic strategy to interrupt transmission has been
recommended, beginning with mapping to assess areas
where MDA is needed; followed by five or more years
of MDA using a combination of two drugs for every eli-
gible individual in endemic areas. This is followed by a
period of post-MDA surveillance; and, ultimately, verifi-
cation of LF elimination.
Currently, 81 countries are considered endemic for
LF, with 1.34 billion persons at risk of infection and
120 million infected. Of the total global burden, 65%
is found in the Southeast Asia Region of WHO
(SEAR), followed by the Africa Region (AFR), with
35%. As shown in Figure 2, of the 81 endemic coun-
tries, 10 (12.3%) are unlikely to require MDA based
on current assessment and 52 (64.2%) currently have
active MDA programmes. Of these, 37 countries have
completed ≥ 5 rounds of MDA in at least some of
their endemic areas. In the African region, progress
has been somewhat slower; of 39 LF-endemic coun-
tries in the African region, 18 (46.2%) have active
MDA programmes.
In 2008, treatment was offered to 695 million people,
representing 51.7% of the at-risk population [1]. That
same year, the cumulative number of albendazole tablets
donated by GSK for LF elimination reached 1.4 billion,
while Merck & Co., Inc. had donated 1.2 billion tablets
of Mectizan® [4].
The resulting global impact and benefits have been
enormous. An estimated 22 million people have been
protected from LF infection and disease, with economic
savings of US $24.2 billion (Figure 3) [5]. Declines in
microfilaremia prevalence have been reported from 131
s e n t i n e ls i t e sa f t e r5r o u n d so fM D A ;6 8( 6 3 % )h a da
100% reduction in prevalence and another 21% had
reductions of 75-99%. Two key factors, baseline microfi-
laremia prevalence and compliance with MDA, influ-
enced the degree of reduction in microfilaremia.
Morbidity management programmes have been imple-
mented in 27 (33.3%) of the 81 LF-endemic countries.
Assessment of several of these programmes has revealed
significant reductions in episodes of adenolymphangitis
(ADL), or “acute attacks,” in persons with lymphoedema
Figure 2 Progress towards LF elimination and status of mass drug administration (MDA) in 81 LF-endemic countries, by WHO region.
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reductions in the prevalence and intensity of infection
with STHs and decreases in onchocerciasis, scabies, and
other ectoparasite infections in areas where these are
co-endemic with LF.
Key remaining challenges include: initiating MDA in
large urban settings and in the endemic African coun-
tries that have not yet started MDA, especially where
Loa loa is co-endemic; implementing and expanding
morbidity management to all LF-endemic countries;
Figure 3 Estimated health and economic impact of the Global Programme to Eliminate Lymphatic Filariasis (GPELF), 2000-2008.
Figure 4 Cumulative percent reduction in episodes of adenolymphangitis (acute attacks) after introduction of basic lymphoedema
management ("foot-care”) in three countries.
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for implementing post-MDA surveillance; and develop-
ing a process to ascertain and verify elimination of LF.
Half-time Around the World: Case Studies
Elimination of Lymphatic Filariasis in India Dr PK
Srivastava, Joint Director of the National Vector Borne
Disease Control Programme, Ministry of Health and
Welfare, reported that LF is endemic in 250 districts in
20 states in India, with an at-risk population of 600 mil-
lion. In 2009, MDA was conducted in all endemic dis-
tricts with co-administered DEC and albendazole. MDA
coverage (the percentage of the eligible population that
receives antifilarial drugs) averaged 85%. Compliance
(the percentage that actually takes the drug) was lower,
but this figure is improving. The overall prevalence of
microfilaremia decreased from 1.24% in 2004 to 0.53%
in 2008 [9].
Challenges for the India programme include the need
for improved social mobilization and supervision to
increase compliance with MDA, especially in urban
areas; maintaining adequate supply and improving hand-
ling and storage of antifilarial drugs; access to technical
expertise for monitoring and evaluation of such a
massive programme; monitoring and surveillance in
implementation units (IUs) that have met current WHO
criteria for stopping MDA; and expanding morbidity
management activities.
LF Elimination in Papua New Guinea Dr Leo Sora
Makita, Health Advisor, Malaria and Vector Borne Dis-
ease, National Department of Health, discussed LF elim-
ination in Papua New Guinea, where an estimated 1
million of its 6.2 million inhabitants are infected with
Wuchereria bancrofti and 3 million are at risk of infec-
tion. The prevalence of infection is as high as 92% in
East Sepik Province. Although the national health plan,
adopted in 2001, called for MDA and morbidity man-
agement in LF-endemic areas, progress has been slow
due to the substantial challenges of dense forests,
rugged terrain and swamps; limited infrastructure; a
highly scattered population speaking 823 different lan-
guages; insufficient human resources; and lack of sus-
tained financial support. The current plan is to
complete LF mapping throughout the country and to
implement MDA in two provinces, adding one new pro-
vince each year.
The Road to LF Elimination in the Philippines Dr
Leda Hernandez, Division Chief, Infectious Disease
Office, National Center for Disease Prevention and Con-
trol, Department of Health, highlighted progress in the
Philippines. Of 80 provinces, 43 are considered endemic
for LF. MDA has been implemented in 38 provinces,
with a mean coverage of 70% (range, 68-89%). In 2010,
the plan is to conduct MDA in all IUs where the preva-
lence of microfilaremia is > 1%. Morbidity management
has developed in partnership with non-governmental
development organizations ( N G D O s )t h a th a v ei n t e r e s t
in hydrocele surgery and home-based disability care.
Guidelines on disability prevention have been developed
and will be disseminated this year.
Mid-term surveys have documented reductions in the
prevalence of microfilaremia and antigenemia in the
IUs, reaching the level required for elimination in 6
provinces.
Key factors facilitating success of the programme have
included: the prioritizing of diseases for elimination by
leading health policy-makers; establishment of a separate
budget within the Ministry of Health for LF elimination;
partnerships with other governmental sectors and with
local and international NGDOs; executive leadership;
and interest in integrated delivery of health services.
Progress Achieved in LF Elimination in Yemen Dr
Abdul Samid Al-Kubati, National Focal Point for Lym-
phatic Filariasis, Ministry of Public Health described the
successful elimination of LF in Yemen. In 2000-2002, 65
suspected LF-endemic districts were mapped using ICT
card tests. Of these, 9 were found to be endemic, with
antigenemia prevalences of 2-40%. MDA was conducted
between 2002 and 2009 in these districts, with an overall
population at risk of ~100,000. By 2006, all IUs com-
pleted 5 rounds of MDA; all but one had reached the
criteria for stopping MDA. With three more annual
rounds of treatment, the criteria for stopping MDA
were reached in this last IU. Vector control and morbid-
ity management were part of the programme. Current
plans are to conduct passive laboratory-based surveil-
lance as well as biennial surveys for infection in the 6-8
year age group using ICT card tests.
LF Elimination in Madagascar Dr Lisy Rasoazana-
miarana, National Coordinator, Lymphatic Filariasis
Elimination Programme, Ministry of Public Health, pre-
sented highlights of the programme in Madagascar,
which has treated 30 of its endemic districts using com-
bined DEC and albendazole. The prevalence of microfi-
laremia in the sentinel sites has been dramatically
reduced. Morbidity management has been implemented
in collaboration with WHO and NGDOs such as Reggio
Terzo Mundo, Handicap International, and Azafady, and
lymphoedema management has been integrated with
leprosy care. In the 30 IUs where MDA has been imple-
mented, 8308 cases of lymphoedema and 7710 cases of
hydrocele have been registered. In 2009, 752 hydrocele
surgeries were performed and 3525 lymphoedema cases
were being managed. Challenges include inadequate
financing and increasing demands by drug distributors
for remuneration.
National NTD Control Programme in Haiti Dr Abdel
Nasser Direny, IMA-World Health Country Representa-
tive and NTD Programme Manager, described the
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addressed both LF and STHs. LF elimination started in
2000 with a pilot programme in the town of Leogane.
By 2005, the national programme included 24 Commu-
nes, but it was temporarily suspended later that year
due to lack of funds. The current integrated NTD pro-
gramme in Haiti is jointly sponsored by the Ministry of
Health (MSPP) and the Ministry of Education (MENFP)
and is supported financial l yb yt h eN T Dp r o g r a m m eo f
the US Agency for International Development (USAID)
and Research Triangle Institute (RTI), as well as by a
grant from the Bill & Melinda Gates Foundation to the
University of Notre Dame.
In 2009-2010, 2.8 million persons were treated, for an
estimated drug coverage of 96% of the total population
(based on imprecise population figures). Morbidity man-
agement is currently limited to a clinic in Leogane,
although some 7000 patients with lymphoedema and
700 with hydrocele have been treated. Dramatic reduc-
tions in prevalence of LF and STH infections were
observed between 2000 and 2005 in Leogane, although
increases in prevalence were seen after MDA was inter-
rupted in 2005 [10].
The massive earthquake on January 12, 2010 tempora-
rily halted the NTD programme, although training and
MDA are scheduled to restart this summer. Indeed,
Haiti has a goal of achieving national-level geographic
coverage in 2011, including the urban area of Port au
Prince.
Goals Scored: Health Impact Achieved
Dr Eric Ottesen presented the results of an analysis of
the health impact of the LF elimination programme dur-
ing its first 8 years (2000-2007) [4]. The analysis
includes health improvements directly related to
reduced transmission of LF and those “beyond-LF.” The
latter benefits, primarily resulting from the broad anti-
parasitic effectiveness of albendazole and ivermectin,
include decreased intestinal worm infections in children;
reduced hookworm-related disease in women of child-
bearing age; and relief of debilitating skin diseases. Data
for this assessment came from the scientific literature
on mechanisms of disease and from existing data on
drug efficacy, MDA coverage, and the age and gender
distribution of populations in filariasis-endemic
countries.
The results suggest that the LF elimination effort is
having a huge impact, with some 16.1 million persons
receiving direct LF benefits (6.6 million newborns pro-
tected and disease progression halted in 9.5 million),
and 32 million disability-adjusted life years (DALYs)
averted. An estimated 146 million persons are estimated
to have received “beyond-LF” benefits during the first 8
years of the programme, including 56.6 million children
treated for intestinal worms, 44.5 million women of
childbearing age treated for STHs, and 45 million per-
sons receiving relief of debilitating skin diseases. Dr
Ottesen noted the many challenges and opportunities
that remain to better quantify the health benefits of LF
elimination.
Goals Scored: Economic Impact
Mr Brian Chu reviewed the economic benefits of the first
8 years of the GPELF. These benefits are experienced by
persons with LF infection, who are protected from pro-
gression of disease; by individuals in affected communities
who are protected from acquiring infection (and subse-
quent disease); and by the public health systems in filaria-
sis-endemic areas. The analysis is based on the direct and
indirect costs averted as a result of preventing hydrocele,
lymphoedema and ADL. Based on the available knowl-
edge of these diseases and the health impact analysis pre-
sented by Dr Ottesen, the programme’s economic benefit
to date is conservatively estimated at $24 billion (Figure
3). The analysis suggests that 78% of benefits are related
to chronic disease, compared to 22% for acute disease,
and that the vast majority of benefits ($20.2 billion) have
been achieved in Asia (SEAR) [5].
Mr Chu cautioned that the “beyond-LF” benefits are
hard to quantify, and therefore were not included in the
model. If 100% of the at-risk population were covered
under MDA, the model estimates that economic benefit
would reach $55 billion. The largest economic gaps
(economic benefits yet to be realized) are in the African
region. In conclusion, Mr Chu noted that the GPELF is
an excellent investment in global health, with impressive
economic rates of return. The success of the GPELF,
measured in economic terms, is a strong affirmation of
the value of investing global health resources in target-
ing the NTDs.
Goals Scored: In Partnership
Dr Adrian Hopkins, Director of the Mectizan Donation
Program, spoke on the crucial role of partnerships in LF
elimination. He defined partnership as a relationship
between individuals or groups of people, characterized
by mutual cooperation and responsibility,f o rt h e
achievement of a specified goal. Partnerships develop
and evolve fruitfully if several conditions are met,
including commitment to common goals; clarity on the
role of each partner; and having established ways to
resolve conflict - which is inevitable.
Dr Hopkins noted that the GAELF involves a “remark-
able mix of partners,” bringing together Ministries of
Health and Finance with various multilateral and bilat-
eral donors and NGDOs. Corporate philanthropy has
provided funding for both research and programme
implementation. Drug donation programmes have pro-
vided funding for mapping, morbidity management,
MDA implementation, monitoring, and operational
research. And NGDOs that previously were dedicated
Addiss and Parasites & Vectors 2010, 3:100
http://www.parasitesandvectors.com/content/3/1/100
Page 10 of 26only to eye care have joined the fight against LF (and
other NTDs).
Dr Hopkins highlighted several examples of partner-
ship and collaboration between Merck & Co., Inc. and
GSK. They have worked to develop a joint drug applica-
tion form, coordinate drug approval and delivery, and
support a joint technical advisory committee. Partnership
among NGDOs has been extraordinarily important to
the GPELF. In 2004, the NGDO LF network was formed
and in 2009 it joined with other groups to create the
NGDO NTD network http://www.ntd-ngdonetwork.org.
Dr Hopkins pointed out that the challenges ahead will
require new partnerships. It will be important to main-
tain the interest and commitment of existing partners;
put greater priority on morbidity management; and
implement effective post-MDA surveillance, which may
not be as interesting to donors as MDA, but which is
needed if we are to reach our goal.
Lessons Learned
Mr Andy Wright, Director of the LF Elimination Pro-
gramme at GSK, began his talk by recalling that, when
the GAELF was established, it resolved to “learn by
doing.” He then highlighted some of the lessons that
have been learned during the last 10 years.
MDA The current two-drug treatment strategy has
reduced the prevalence of microfilaremia to < 1% in
many settings. Community mobilization has been crucial
to achieving the coverage necessary for success. It is also
clear that five years of MDA will not stop transmission
in all settings, and that additional or enhanced interven-
tions are needed in challenging areas (e.g., Loa loa-ende-
mic countries and urban settings).
Science Mr Wright emphasized the important role
played by science in guiding strategy, assessing drug effi-
cacy, monitoring and evaluation, and determining the
number of annual rounds of MDA required to stop LF
transmission.
Partnership T h eo p e na n di n c l u s i v en a t u r eo ft h e
GAELF, with its light, regional, and representative gov-
ernance structure, has worked well. The GAELF has
matured as a partnership, and this has been facilitated
by transparency and communication among partners.
Fund-raising Several lessons related to fund-raising
have been learned, including the importance of engage-
ment by Ministries of Health; the role of international
advocacy; and the attractiveness to donors of an inte-
grated programme of NTD control.
Morbidity management Although morbidity manage-
ment has scaled up more slowly than MDA, it is a vital
component of the GPELF that can enhance MDA
uptake [11]. The effectiveness of basic lymphoedema
management has been demonstrated in several settings;
it can decrease ADL incidence, reduce lymphoedema
progression, improve quality of life, and enhance eco-
nomic productivity [7].
Wednesday, 2 June, 2010
Half-time Scores in Morbidity Control
Chair: Professor Dato C.P. Ramachandran
Impact of MDA on Clinical Disease
Charles Mackenzie, Professor of Parasitology and Diag-
nostic Investigation at Michigan State University,
observed that accurate data are not available on the
number of people affected with various forms of LF-
related disease, and this limits our capacity to plan for
and provide adequate care.
Since it began in 2000, the GAELF has continued to
learn about the impact of MDA on clinical disease. Data
from Tanzania indicate that MDA dramatically reduces
the incidence of new cases of clinical disease. Dr Mack-
enzie argued that the incidence of clinical disease may be
a critically important indicator of programme success. In
Tanzania, MDA has been associated with reduced inci-
dence, duration, and severity of ADL in persons with
chronic morbidity [12]. Studies by Professor RK Shenoy,
in India, also indicate that antifilarial drug treatment has
an effect on sub-clinical disease in children (see below).
As the GAELF enters the next decade, Dr Mackenzie
called for a clearer understanding of the extent and
magnitude of clinical LF; more effective treatment,
including improved wound and surgical care; and more
widespread patient support systems, which have been
piloted in Brazil, India, Tanzania, and elsewhere. He
argued for improved funding and technical support for
morbidity management, especially for specific patient
needs, such as specialized shoes; assistance in job devel-
opment and re-entry into the commercial community;
psychological support; and comprehensive care
packages. He stressed the need for more widespread
innovation, such as the President Kikwete Fund, which
supports hydrocele surgery in Tanzania.
Prevention of Lymphoedema in Children
Professor RK Shenoy, Chief of the Filariasis Research
Unit at TD Medical College in Kerala, India described a
s t u d yt h a th ea n dh i sc o l l e a g u e sr e c e n t l yc o m p l e t e d
[13]. The study addressed the degree to which antifilar-
ial drug treatment reverses clinical and sub-clinical dis-
ease associated with Brugia malayi infection in children
3-15 years old [14,15].
On enrolment, children were screened for microfilare-
mia, anti-Bm IgG4 antibodies, and clinical disease. Dop-
pler ultrasonography and lymphoscintigrapy were done
on all four limbs. Of 100 children enrolled, 32 were
microfilaremic; 29 had clinical LF disease; and 39 had
IgG4 antibodies indicative of B. malayi infection. All
children were treated with a single-dose combination of
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every 6 months for 3 years.
A total of 18 adult worm “nests” were seen on ultra-
sound in 14 children, the youngest being 3 years old.
Lymphatic vessel dilatation was detected by lymphoscin-
tigraphy in 80% of enrolled subjects. At 36 months, lym-
phatic dilatation had reversed in 90% of affected
children, and three of the four cases of clinical lymphoe-
dema had resolved.
Integrated Morbidity Control: LF, Leprosy, and Diabetes
Footcare
Dr Pierre Brantus, Consultant Physician to Handicap
International, emphasized that strategies for morbidity
management and disability prevention have to be based
on scientific knowledge and yet implemented at the
community level. The current WHO strategy for inte-
grated morbidity management developed out of scienti-
fic research. It also is rooted in observations that the
most consistent and lowest-cost care can be provided in
the home, rather than an institution; that community-
level programmes are most effective; and that psycholo-
gical support is necessary for many patients. It is a com-
prehensive approach.
Dr Brantus noted several arguments for integrating LF
morbidity management and disability prevention with
care for other diseases. First, at the community level,
the same health workers and general approaches are
often shared, so integration can reduce costs. Second,
fund-raising is often more successful for integrated pro-
grammes. Third, integrating LF elimination into NTD
control programmes requires integration of morbidity
management as well as MDA. Several disabling diseases
could be integrated with LF disability prevention,
including leprosy, diabetes, and Buruli ulcer, among
others. Treatment for all these diseases involves hygiene,
skin care, wound care, appropriate footwear, and move-
ment. All could be addressed with similar home- and
community-based approaches.
Mary-Jo Geyer, Professor of Health and Rehabilitation
Sciences at the University of Pittsburgh, reported on the
“Legs to Stand On” project. The first International
Cross-Diseases Conference on Lower Limb Care in
Developing Countries had been held recently in Accra,
Ghana. Attendees included officials from international
and national-level NGDOs, health professionals,
patients, patient advocates, policy makers and pro-
gramme managers, all with knowledge, responsibilities
or expertise in LF, diabetes, leprosy, Buruli ulcer, and
other lower limb conditions.
The goal of “Legs to Stand On” is to translate state-of-
the-science evidence into cross-diseases curricula,
educational materials, and programme guides for the
implementation of lower limb care programmes to pre-
vent disability in low-resource countries. The conference
participants reviewed the current state of lower limb
care programmes internationally and they used a flexible
and comprehensive group decision-making method that
was representative of all stakeholders.
The participants drafted detailed “problem state-
ments” for several key issues (e.g., footwear), which
addressed current needs, requirements, and specifica-
tions. The conference organizers are planning to hold
a consensus conference in the fall of 2010 and to
begin producing and using standardized technical tools
in 2011.
Hydrocele Surgery
Dr Serigne Magueye Gueye, Professor and Chair of
Urology, University of Cheikh Anta in Dakar, Senegal,
updated the GAELF on the West African LF Morbid-
ity Management Programme, which helps to train and
equip surgeons to repair hydrocele, the most common
chronic manifestation of bancroftian filariasis. He
explained why surgery that spares the hydrocele sac
may result in suboptimal outcomes in LF-endemic
areas, and summarized key points for hydrocele sur-
gery recommended by the programme. These include
proper pre-operative evaluation to exclude scrotal
lymphoedema; the use of local anaesthesia; an
approach that uses a midline incision; meticulous
haemostasis; proper post-operative dressing and ban-
daging; and complete resection of the hydrocele sac
[16]. The West Africa LF Morbidity Management
Programme has had considerable success. Some 3874
surgeries were performed during training courses,
which have taken place in 11 countries. 415 health
workers have been trained, and the work has been
highlighted at major international urology meetings.
The programme also provided training in connection
w i t ht h eP r e s i d e n tK i k w e t eF u n df o rh y d r o c e l es u r -
gery in Tanzania.
To expand access to surgery for men with hydrocele
in LF-endemic areas, it will be necessary to reposition
LF within national health plans and to increase training
and research through a network of public and private
partners, including universities, United Nations (UN)
agencies, and NGDOs. In conclusion, Professor Gueye
stressed that hydrocele surgery can be done even in
remote areas, as long as training is adequate. He called
for the establishment of a bro a d e rn e t w o r kf o rm o r b i d -
ity management and training, as well as a GAELF Mor-
bidity Management Expert Group.
Economic and Psychosocial Impact of Hydrocele and the
Benefits of Hydrocelectomy
Professor John Gyapong, Director, Research Develop-
ment Division, Ghana Health Service, presented preli-
minary results of a study now underway in Ghana,
where hydrocele is a public health problem. In 2006,
9,931 cases of hydrocele were registered in the country.
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cele on productivity and quality of life, but little atten-
tion has been given to how these factors change
following surgical repair of hydrocele (hydrocelectomy).
In the study, 215 men were interviewed before under-
going hydrocelectomy and 3, 6, 12, and 18 months after
the operation to assess productivity, quality of life, cost
of treatment, and clinical status. Beliefs about the cause
of hydrocele varied, but few men considered it to be
associated with a mosquito-borne parasite. Only 15% of
men had ever sought care for hydrocele; for those who
did, treatment consisted primarily of herbal preparations
or puncturing the scrotal skin with a hollow reed to
drain the fluid. Twelve months after hydrocelectomy,
85% of men were considered to be in “perfect health”
based on several indicators including mobility, self-care,
performance of usual activities, pain or discomfort, and
anxiety/depression. The men also reported improved
economic status and family life. Analysis of the data is
ongoing.
Integrative Self-care through Community Participation for
Morbidity Management
Mr Naveen Krishna Tarur, of the Institute of Applied
Dermatology (IAD) and Infosys Tech Ltd., described an
integrative self-care programme for lymphoedema man-
agement in Kerala, India [17,18]. He argued that lym-
phoedema treatment should incorporate self-care and be
low-cost, locally available, and administered at the com-
munity level. Naveen acknowledged, with thanks, that
the Government of India’s Department of AYUSH
(Ayurveda Yoga, Unani, Siddha, and Homoeopathy) has
sponsored community-level morbidity management for
1,000 poor patients in two filariasis-endemic districts of
India, based on IAD’s integrated treatment model. This
project is ongoing. He also called for a country-wide
programme for India, which could be rolled out at the
community level. The programme advocated by the IAD
integrates the principles of Ayurvedic medicine; western
biomedicine; Yoga (Pranayama); traditional skin care;
and patient counselling and education.
Discussion An animated discussion followed these pre-
sentations, which touched on the evidence (and lack
thereof) for the effectiveness of various treatments for
lymphoedema; the most effective components of existing
treatment packages; the role of surgery; the best indica-
tors of clinical and sub-clinical improvement; the lessons
that have been learned from programmes for managing
other chronic diseases, such as leprosy; and the impor-
tance of patient education. The varying degree to which
these diseases are stigmatized in different settings may
pose certain challenges for integration, especially for
support groups. However, recent experience in Indone-
sia suggests that leprosy patients in mixed support
groups progressed better than those participating in
leprosy-only support groups (Professor Geyer, personal
communication).
Half-time Strategy: Future Research and Application
Chair: Dr Eric Ottesen
Strategies for the End Game: Operational Research Update
Dr Dominique Kyelem, Program Director at the LF Sup-
port Center, Task Force for Global Health, provided an
update on operational research that will inform strate-
gies for the “end game” - especially for post-MDA sur-
veillance to detect possible resurgence in LF
transmission. It is accepted as a “working hypothesis”
that transmission will be interrupted when microfilare-
mia prevalence declines to < 1%, based on the experi-
ence of China.
The current Bill & Melinda Gates Foundation grant to
the GAELF for operational research is focused on devel-
oping improved tools and sampling strategies for post-
MDA surveillance. A guide for programme managers is
being developed to assist them with survey methods and
sample size calculations for post-MDA surveillance. The
guide will help programme managers determine the “cri-
tical value” of positive tests among children 6-7 years
old, above which MDA should be continued. The role
of xenomonitoring in areas with Culex-transmitted filar-
iasis is also being explored with support from this grant.
Operational research and programme experience indi-
cate that, when five years of MDA are insufficient to
reduce microfilaremia to levels that will not sustain
further transmission, several factors may be in play.
These include high prevalence and density of pre-MDA
microfilaremia, low drug coverage or compliance, char-
acteristics of the local vector, the drug regimen used,
and other factors, such as the lack of social cohesion,
especially in urban environments. In such situations,
alternative strategies may be needed, including modified
drug regimens (e.g., biannual MDA), vector control
measures, or perhaps antibiotic treatment. Dr Kyelem
emphasized that LF elimination is feasible, even in areas
with the greatest challenges, but that continued opera-
tional research will be necessary for providing guidance
to the GPELF [19].
Diagnostics: Development of Applicable Tools
Professor Gary Weil, Professor of Medicine at Washing-
ton University School of Medicine, emphasized the need
for practical diagnostic tests, and noted the important
role played by the antigen-detection based ICT card test
for mapping LF-endemic areas in many parts of the
world. He reported findings from a study in Egypt,
where, with 5 rounds of MDA, the prevalence of antifi-
larial antibody (Bm14 IgG4) decreased more dramati-
cally in children 6-10 years old than did antigen or
microfilaria levels [20]. The prevalence and incidence of
these markers decreased with each consecutive MDA.
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antigenemia, and antibody levels for programme deci-
sion-making. He noted the need for better and less
costly tests; the lack of firm consensus on programmatic
endpoints; the paucity of resources for monitoring and
evaluation; and the need for applied field research to
optimize the utility of existing and newly developed
tests.
Role of Vector Sampling - Xenodiagnosis in Post-MDA
Surveillance
Dr Sandra Laney, Research Scientist at Smith College,
reviewed the advantages of xenodiagnosis, i.e., detection
of infection in the mosquito vector, to monitor levels of
LF infection in the community. There are two major
approaches to xenodiagnosis: dissection of the vector to
detect the parasite; and molecular xenodiagnosis (MX),
using polymerase chain reaction (PCR) techniques. Cur-
rent MX detects parasite DNA or RNA in the mosquito
and can distinguish among filarial species. Dissection is
less sensitive than MX.
Xenodiagnosis can help determine whether infection
is present; it can serve as an indicator of transmission
potential; and it can detect changes in transmission. It
is less intrusive and more acceptable to the commu-
nity than blood collection. Field research in the con-
text of LF elimination programmes in Papua New
Guinea, Egypt, and Tanzania has documented declines
in mosquito infection rates with consecutive rounds of
MDA [20].
More research is needed to make MX fully pro-
grammatically applicable. MX data may be hard to
interpret programmatically in settings where vector
control has been implemented, e.g., where bednet
coverage is high or indoor residual spraying of insec-
ticides is used. Still unknown is the effectiveness of
MX over wide geographic areas; sampling strategies
and sample sizes across regions; and how data on
human infection correlates with MX. Studies are
underway to assess the potential of xenomonitoring
to detect resurgence of transmission following cessa-
tion of MDA, as has been used in onchocerciasis pro-
grammes in Africa. Additional work is needed to
simplify sampling strategies, reduce cost, and develop
better methods for mosquito collection and for use of
PCR in the field.
Post-treatment Surveillance for LF: Togo Case Description
Dr Yao Sodahlon, Associate Director, Mectizan Dona-
tion Program, described a comprehensive system for
post-MDA surveillance that has been established in
Togo, where mapping with ICT in 2000 had indicated
that LF was endemic in 7 districts. After 10 years of
MDA (7 years with full geographic coverage), monitor-
ing data suggested that transmission had been inter-
rupted, so MDA was halted and post-MDA surveillance
was initiated. The goal of this surveillance is to ensure
that there is no ongoing LF transmission and to prevent
re-introduction through prompt case detection and
response. The surveillance system is low-cost and has
been integrated as much as possible with other health
activities. It has several components.
First, areas that were excluded from MDA on the basis
of initial mapping are being re-mapped in 2010, using the
RAGFIL method with a finer grid (e.g., 10 or 35 km) than
was used initially (50 km). Second, surveys were done in
two districts in 2009 to determine whether to stop MDA;
these provided a baseline for post-MDA surveillance. In
these surveys, 1548 school children 6-7 years old were
tested by ICT; 2 (0.1%) ICT-positive cases were detected,
one who was microfilaremic. Screening for microfilare-
mia around the index case revealed no infection. Screen-
ing will be repeated in 2011.
Third, laboratory-based surveillance was started in
2006, involving 40 laboratories that examine thick
smears for malaria. All malaria slides that are collected
at night also are read for microfilaria. In 2010, this sys-
tem was evaluated. Some 4000 slides are read each year.
Two microfilaria-positive slides have been detected, one
from a nomad who was lost to follow-up and the other
from a person living in a district considered non-ende-
mic for LF. Finally, plans are being developed to test
donated blood at blood banks using the ICT or the
Og4C3 ELISA. However, the geographic distribution of
blood donors is not geographically representative, so
this approach may require further evaluation.
The second objective of post-MDA surveillance is to
prevent recurrence or reintroduction of infection. This
has been achieved by intensified mapping and labora-
tory-based surveillance in areas that border other areas
of high-risk (e.g., other LF-endemic countries). The
response to any ICT-positive result is to re-test that per-
son for microfilaremia and, if positive, to treat. An epi-
demiologic assessment is made to determine if the case
is local or imported. Community surveys will be done in
areas suspected of being the source of infection, and
MDA will be re-started if necessary.
LF and NTDs - The Chicken or the Egg: How do we Stop
MDA?
Dr John Gyapong invited participants to recall the WHA
resolution 50.29, which urged member states to under-
take four key actions: 1) Take advantage of recent
advances in understanding LF and its control; 2)
strengthen local LF programmes and their integration
with the control of other diseases, particularly at the
community level; 3) strengthen training and capacity for
research, management, and laboratory diagnosis; and 4)
mobilize support from all relevant sectors.
In an integrated programme, how can we stop MDA
for LF when there is “unfinished business” for other
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tribute to a gap between knowledge and action, the
“know-do” gap. These include the complexity of inte-
grated programmes; inadequate evidence and data for
decision-making; challenges with existing guidelines; and
inadequate funding for monitoring and evaluation activ-
ities. Dr Gyapong suggested several practical issues to
consider, including the feasibility of joint monitoring
and evaluation for preventive chemotherapy; equipping
country programme managers to adequately monitor
and evaluate their interventions; and improving the
capacity for preventive chemotherapy programmes to
collect the minimal data needed for the global pro-
gramme. He noted that the needs for epidemiological
assessment may differ among NTDs but that it’s possi-
ble to plan so that data can be pulled together to make
informed and integrated decisions [21,22].
Dr Gyapong argued that an integrated NTD control
programme should not be integrated only at the level of
programme implementation and advocacy. Rather, deci-
sions about stopping MDA al s os h o u l db em a d ei na n
integrated context, and this should be based on inte-
grated monitoring and evaluation data. He challenged
the GAELF to move from monitoring processes to
assessing impact, and urged that the GAELF come to
consensus on what will be needed to achieve this.
Discussion In the discussion that followed, Dr Ottesen
highlighted the important role of research in the
GPELF, and pointed to the research now underway to
refine guidelines for stopping MDA and to fit these
guidelines into the “new world of NTDs.” Comments
were made by several participants on the recently-
developed rapid test for Brugia infection and its perfor-
mance in the field. Discussion also addressed xenomoni-
toring and different methods of mosquito collection.
Half-time Strategy: Major Technical Challenges
Chair: Dr Frank Richards
LF in the City - The Urban Problem
Dr Margaret Gyapong, Director of the Dodowa Health
Research Centre, reviewed the challenges presented by
rapid urbanization. Some 38% of Africans live in
urban areas, and MDA coverage in urban areas in
Africa has been sub-optimal (generally 40-50%). Con-
tributing to this is the fact that people who live in
cities tend to be busier, making social mobilization
more difficult; populations are heterogeneous, with
complex social, economic, and religious structures;
and urban dwellers place a higher priority on privacy.
In urban areas, communities tend to be defined by
affiliation or identity, rather than by geographical
proximity. Because of these differences, simply import-
ing MDA strategies from rural to urban areas is not
likely to be successful.
Specific challenges to MDA in urban areas begin with
defining and demarcating the community; slums are
often immediately adjacent to the high-rise apartments
of some of the richest - and certainly the “non-poor”.
Community-directed treatment (ComDT) and use of
volunteer distributors does not work as well in urban
areas. Elites, who may be at risk of LF in urban areas,
perceive their risk as being low, consider LF a “disease
of the poor,” and limit access through security guards
and dogs. In such a setting, what is the appropriate
denominator for calculating drug coverage?
However, with appropriate preparatory work these
problems can be addressed. Populations can be charac-
terized not only by location but also by socioeconomic,
religious, and demographic status. Existing informal net-
works can contribute to MDA implementation. Knowl-
edge of existing health and related interventions can be
helpful. Regardless of how the community is defined, it
needs to be engaged and consulted to determine the
best approaches. It is important to involve community
members, to seek their input and suggestions as colla-
borators, and to empower them to make decisions and
implement and manage change.
Urban MDA will require more involvement of the pri-
vate sector than is typically the case in rural areas. This
includes private medical practitioners; hospitals; private
clinics; other non-health sectors; politicians; and others.
A team approach should be used, with as many stake-
holders as possible, for advocacy planning.
Discussion In the discussion that followed, Dr Frank
Richards suggested the label “white coat environments”
for urban areas, because urban dwellers prefer to take
medication only from “professionals” wearing white
coats. Professor Molyneux raised the question as to
whether Culex in West Africa may be genetically insus-
ceptible to infection with W. bancrofti - which would
have significant implications for urban transmission, and
this was discussed further.
LF in the Forest
Dr Joseph Kamgno, Director of the Filariasis Research
Centre in Cameroon, reviewed the challenges posed by
co-endemic LF and Loa loa infection in Central Africa.
In the forested areas of these countries, serious adverse
events (SAEs) following treatment with ivermectin have
been a major obstacle to expansion of both onchocercia-
sis control and LF elimination programmes. The main
risk factor for SAEs is high density of Loa loa microfi-
laria in the blood (especially above 10,000 per mL) [23].
Operational measures, including surveillance, have
been implemented at regional and community levels to
reduce the frequency and improve outcomes of persons
with SAEs. In LF-endemic areas of Central Africa where
MDA with ivermectin for onchocerciasis has already
been implemented, the risk of SAEs is low; MDA can be
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nation. In areas where no MDA has yet taken place,
research is underway to determine if twice-yearly treat-
ment with albendazole alone can sufficiently reduce Loa
loa microfilarial densities to safe levels. Insecticide-trea-
ted bednets also may be useful. Research is ongoing to
assess cofactors associated with SAEs, including Loa loa
strain differences and human genetic factors. Program-
matic approaches also are being evaluated, e.g., the feasi-
bility of test-and-treat approaches, and the impact of
limiting MDA to younger people at lower risk of SAEs.
Detailed mapping of Loa-endemic areas in Central
Africa continues.
Discussion The ensuing discussion focused on the
pathophysiology and treatment of SAEs, on the need for
accelerated research, and on various strategies to over-
come the challenges posed by Loa loa for LF elimination
in Central Africa.
LF in Conflict Zones
Dr Adrian Hopkins reflected on the specific challenges
to LF elimination in zones of conflict. He noted that, in
most conflict zones, only a small percentage of the
population is actively engaged in fighting. Once fighting
has erupted, the short-term needs of the population are
for food, water, and shelter. Health concerns are a
longer-term priority, although health quickly becomes a
priority in refugee camps, which can be quite organized.
The special challenges of working in conflict situations
include the risk of violence; destruction of infrastruc-
ture, medical records, and research data; reluctance to
make any further investment in infrastructure, offices,
schools, or hospitals; and shortages of human resources,
such as well-trained staff.
Even with these challenges, however, MDA can be
successful in such settings. For example, onchocerciasis
programmes persisted and even expanded during peri-
ods of conflict in the Central African Republic, Sudan,
and the Democratic Republic of the Congo.
Lessons from these experiences include the impor-
tance of investing in communities, which can be quite
resilient; the need for flexibility and mobility; the
increased cost of doing business in zones of conflict;
and the need for appropriate infrastructure (e.g., laptop
computers rather than desktops). With adherence to
these principles, MDA can be realistic for many areas in
conflict [24,25].
LF after MDA
Dr Mwele Malecela noted that strategies for stopping
MDA and initiating post-MDA surveillance still need to
be fine-tuned. However, the programmatic benefits of
LF elimination will persist even after LF has been elimi-
nated. Other NTDs will likely remain, and the infra-
structure that was developed to eliminate LF can be
transformed for use with other NTDs. Similarly, the
benefits of strengthening the health system for LF elimi-
nation will persist. These benefits include human
resources; controls and procedures for managing the
drug inventory; recording and reporting systems; and
cascade training programmes. Community-based distri-
butors trained for LF might well play a role as bona-fide
health workers in an expanded health system.
Morbidity management activities will continue, includ-
ing patient support and advocacy groups and
home-based health care for lymphoedema, preferably
integrated with care for other non-communicable dis-
eases. The need for hydrocelectomy will continue, as
will the need for psychological counselling (many men
with hydrocele in the recent “hydrocelectomy camps” in
Tanzania reported being suicidal). The President Kik-
wete Fund for hydrocele surgery was begun in response
to awareness of the magnitude of the problem - more
than 15,000 affected men - which called for action.
In conclusion, Dr Malecela reiterated that the patient
remains central to the LF programme, and urged pro-
gramme managers in the next decade to focus on
surveillance.
Discussion Several topics were addressed in the discus-
sion, including the advantages and disadvantages of
using cellphones for surveillance, patient support
groups, provision of mental health services, and timely
notification of health workers regarding ADL episodes
in patients with lymphoedema.
Half-time Strategy: Alternative Strategies for the Second
Half
Chair: Professor Moses Bockarie
Filariasis Chemotherapy for the Next Decade
Professor Gary Weil reviewed the history of drug ther-
apy for LF, beginning in 1947 with DEC. While two-
drug combinations given in a single annual dose are the
mainstay of LF elimination, they have some limitations.
They are not completely effective against the adult
worm; they are associated with adverse events; and they
cannot safely be used in areas with intense Loa loa
transmission. Lack of compliance is an issue with cur-
rent approaches to MDA; a recent study in Egypt by El-
Setouhy and colleagues showed that 7% of people had
never taken the drug after 5 rounds of MDA [26]. The
potential for drug resistance is also a concern. Although
resistance to ivermectin and albendazole has not yet
been observed in LF parasites, few data exist or are
being collected.
Professor Weil summarized some of the current and
planned research on filariasis chemotherapy. Recent
data suggest that repeated doses of albendazole alone
are safe in Loa-endemic areas, and may be fairly effec-
tive in reducing W. bancrofti microfilaremia. Phase 3
clinical trials are currently testing moxidectin, a drug
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group of studies, known collectively as Death to Onch-
ocerciasis and Lymphatic Filariasis (DOLF), is now
underway, funded by the Bill & Melinda Gates Founda-
tion. Large-scale community trials of biannual
“enhanced” MDA will include epidemiologic modelling
and cost analyses (Peter Fischer, Principal Investigator
[PI]). Randomized clinical trials will assess the efficacy
of new drug combinations and treatment schedules
(James Kazura, PI), and flubendazole is being tested in
pre-clinical studies for its potential as a macrofilarici-
dal drug (Charles Mackenzie, PI).
Professor Weil suggested that more frequent MDAs
over a shorter period could be more effective, reduce
overall costs and programme duration, and decrease the
likelihood of drug resistance.
Role of Antibiotics Against Wolbachia: Can it Play a Role in
the Endgame?
Mark Taylor, Professor of Parasitology at the Liverpool
School of Tropical Medicine, spoke about the potential
role of antibiotics against Wolbachia, symbiotic bacteria
that are found in W. bancrofti, B. malayi and Oncho-
cerca volvulus. Treatment with doxycycline eliminates
Wolbachia from these parasites, leading to permanent
sterilization, sustained loss of microfilaraemia and
potent macrofilaricidal activity. Studies in patients with
lymphoedema who were treated with doxycycline have
shown reductions in lymphatic vessel diameter and lym-
phoedema severity, as well as improvement in skin con-
dition [27]. Treatment with doxycycline also reduces
severity of hydrocele in men who are actively infected
with W. bancrofti [28].
A 4-8 week course of doxycycline is highly effective
and well-tolerated, but the logistics of delivering long
courses of treatment and contraindications in children
and during pregnancy are barriers to the widespread
introduction of doxycycline for MDA. However, Wanji
and colleagues recently completed a study of commu-
nity-directed delivery of a 6-week course of doxycycline
in an area co-endemic for onchocerciasis and loiasis, in
which compliance was 98% and therapeutic coverage
was 74%, demonstrating that in more restricted areas
this option is both feasible and achievable [29].
Professor Taylor described the Anti-Wolbachia Con-
sortium (AWOL), a five-year, $23 million research pro-
gramme funded by the Bill & Melinda Gates Foundation
to find new anti-Wolbachia treatments compatible with
community-treatment programmes for human filariasis.
Activities include refining current regimens that use
doxycycline; developing assays to rapidly screen and test
new drugs that may be even more effective than doxycy-
cline; studies to better understand the role of Wolbachia
in filarial worms; and identifying the genes that are
essential for the organism’s survival.
Role of Vector Control
Professor Moses Bockarie noted that LF is the only vector-
borne disease that is transmitted by more than 4 genera of
mosquitoes, each with different features and capacities for
transmission. The good news for LF elimination is that,
even in areas with the most efficient vectors, MDA alone
can interrupt LF transmission using two-drug combina-
tions. However, 19 countries with active LF transmission
have not yet begun MDA. Of these, 13 have fragile infra-
structures or are in post-conflict situations; six others are
s t a b l e ,b u tw i t hl o wL Fe n d e m icity. In 17 of these coun-
tries, Anopheles is the principle vector for LF [30].
This is good news for LF elimination. The efficiency with
which Anopheles transmits LF is low compared to other
vector species, and Anopheles also is the principle vector for
malaria. Early experience with DDT house-spraying in the
Solomon Islands, Papua New Guinea, Togo, and Indonesia
showed dramatic effects on LF transmission [30], and insec-
ticide-treated bednets (ITNs) are even more effective than
DDT as a malaria control strategy. A study in Liberia and
one currently underway in Nigeria have documented the
effectiveness of ITNs in reducing the density of LF infection
in mosquitoes under conditions of universal bednet cover-
age [31]. Together, these data suggest that ITNs can have
significant impact on LF transmission.
Thus, Professor Bockarie suggested that in these 17
countries the LF elimination strategy should not be
“MDA and vector control if possible” but, rather, “MDA
and vector control.” ITNs are being widely distributed for
malaria control, so there is reason for hope.
Discussion An animated discussion followed that
touched on the role of vector control and the strength
of scientific evidence that ITNs reduce LF transmission,
especially within national programmes. Other comments
focused on the feasibility and effectiveness of twice-
yearly albendazole in Loa-loa co-endemic areas and the
advantages and disadvantages of various recommenda-
tions put forward by the presenters, particularly the fea-
sibility of incorporating antibiotic treatment into
operational programmes.
Thursday 3 June, 2010
Second Half 2010-2020: Strategy for the Next Decade
Chair: Dr Dirk Engels
The Vision Moving Forward
Dr Dirk Engels presented WHO’s vision for LF elimina-
tion in the context of an integrated, multi-disease
approach. He reviewed the major challenges ahead and
suggested action points for each one.
Getting started MDA should be initiated in the 19
countries that require it but have not yet started. Of
these, 16 are located in Africa [1].
Loa loa In Central Africa, Loa loa co-endemicity pre-
sents a major barrier to initiating LF elimination
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native or provisional strategies.
Upscaling In the countries where MDA has already
begun, it is critical to upscale MDA to full geographic
coverage. 70% of the total at-risk target population,
919.5 million people, live in the countries of India, Indo-
nesia, Bangladesh, Nigeria, and the Democratic Republic
of Congo. Achieving and maintaining full geographic
coverage is particularly important in these countries.
Urban populations Strategies must be developed to
effectively treat urban populations where this is needed,
particularly in Africa and Asia.
Disability management Only 27 countries have active
disability management programmes; this needs to be
expanded and linked to other disability management
programmes (e.g., for trachoma or leprosy). It should
include home-based counselling and strengthening of
the health system through improved NTD case
management.
Guidelines An urgent need exists for refined guidelines
for stopping MDA and for post-MDA surveillance. Such
LF-specific procedures and guidelines are a priority for
WHO. However, these guidelines should be part of an
integrated monitoring and evaluation package; MDA
coverage will be the basic indicator, but the guidelines
will also include other disease-specific indicators.
Integration In addition to integrated monitoring and
evaluation, WHO envisions an integrated approach to
three key areas: preventive chemotherapy, disability
management, and vector control.
Dr Engels presented milestones proposed by WHO in
a draft strategic plan for the GPELF (Figure 5), all of
which lead to the goal that all LF-endemic countries will
either be verified free of LF or under post-MDA surveil-
lance by 2020. He stressed the need for harmonizing the
language used in the GPELF with that of other NTDs,
and suggested that the phrase “elimination as a public
health problem” be interpreted as meaning prevention
of morbidity.
The public health problem to which WHA resolution
50.29 refers has to do with morbidity, not just trans-
mission of the parasite. One articulation of a morbid-
ity-related goal for 2020 might be, “To provide access
to preventive treatment and care for every individual
living in LF-endemic areas, through an integrated
approach.”
Building Partnerships for Morbidity Control
Dr Pierre Brantus cited the need to develop partnerships
to improve implementation of morbidity management
and disability prevention within the GPELF. He defined
partnership as a relationship between individuals,
groups, diseases or health problems that is characterized
by mutual cooperation, responsibility, and interaction
for the achievement of a specified goal.
Dr Brantus outlined the nature of various partner-
ships. Some partnerships develop out of a desire to
combine or integrate activities.W i t h i nt h eG P E L F ,
examples of these include partnerships between MDA
and disability prevention activities, between wound care
and lymphoedema management, and among the various
programmes that focus on LF, leprosy, diabetes, or Bur-
uli ulcer. Other partnerships are established primarily to
combine and share resources. Examples include partner-
ships among NGDOs; between scientific institutions and
organizations focused on operations or delivery of ser-
vices; and between Ministries of Health and NGDOs.
Major challenges for partnerships in morbidity man-
agement and disability prevention include: improving
involvement and collaboration at the country level;
modifying the way donors fund projects and the rules
for managing partnerships; and developing new partner-
ships to address the problem of hydrocele, which will
require recruitment of new donors and organizations
involved in promoting reproductive health [8].
Building Partnerships for Implementation
Professor Bernhard Liese, Chair, International Health
Department, Georgetown University, commented on the
diverse nature of the GAELF partnership, which involves
LF-endemic country governments; drug donation pro-
grammes; multilateral and bilateral donors; private foun-
dations; and NGDOs.
The central issue for the next decade of the GAELF is
access to funding that will allow programmes to go to
scale. The key constraint to scaling up has been lack of
funding rather than technical issues, governance, or
inadequate operational research. Both the availability
and the stability of funds are needed.
From the perspective of funding, the contribution of
various partners within GAELF varies considerably.
Official development assistance from donor govern-
ments for health contributes only 0.6% of all funding
for NTDs [32]. In contrast, the drug donation pro-
grammes have been major and reliable partners, in part
because there is no replacement effect related to their
donation. In other words, Ministries of Finance of LF-
endemic countries do not reallocate their health budgets
to other sectors in response to drugs donated to the
health sector, whereas they often do so if direct funding
for other health activities is received from donor
governments.
To increase the level of funding, donors should con-
sider pooled-financing mechanisms, such as a Trust
Fund at the World Bank. The Trust Fund of the African
Programme for Onchocerciasis Control (APOC) is one
such example. Advantages of such mechanisms include
the fact that the funds are usually non-designated, and
therefore flexible; they are generally stable; and it is
easier for international development banks to provide
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ance issues and the role of the secretariat.
Within LF-endemic countries, both the Ministry of
Health and the Ministry of Finance should treat LF as
an “essential expenditure” line item in the national bud-
get. Potential partners within the national government
are often overlooked, such as the national health insur-
ance system and hospital network. Morbidity manage-
ment has been the most neglected part of LF
elimination. To develop, it should be viewed within the
context of health system strengthening. NGDO support
for morbidity management will be critical for the next
decade.
Developing the Operational Research Agenda
Dr Julie Jacobson, Senior Program Officer, Bill &
Melinda Gates Foundation, reviewed some of the opera-
tional research projects supported by the Foundation.
She argued that history is filled with failed attempts at
disease elimination or eradication, and that these failures
can provide important lessons. For example, eradication
of yellow fever was attempted without the research
necessary to recognize the importance of non-human
reservoirs. She urged the GAELF6 participants to ask
the “hard questions.” Are we willing to fail? If not, what
must we put in place to meet our targets? Why have
some LF programmes not succeeded in interrupting
transmission after 5-9 years of MDA? How will the pro-
blem of co-endemic loiasis be addressed in Central
Africa? What are our strategies for urban MDA and for
post-conflict and conflict settings? What will be the
impact on LF of integration with other NTD pro-
grammes, and how do we ensure that integration helps
the cause of LF elimination?
Several challenges present themselves for the next
decade of the GPELF. Countries that remain highly
endemic for LF are precisely those that have the least
experience with LF. Modified strategies and thresholds
must be developed as different approaches are put into
play. Conflict and post-conflict situations, the perceived
low priority of LF in the remaining countries, and the
need for clear guidelines represent additional challenges.
Discussion An enthusiastic discussion followed on the
importance of operational research; the intent of the ori-
ginal WHA resolution; and the role of morbidity man-
agement, including the fact that it has not progressed as
quickly as MDA. Several speakers and participants
noted that the focus on integration provides a unique
opportunity to learn from other health programmes
such as those addressing leprosy, obstetric fistula, or
malaria.
Dr Engels suggested that the next WHO 10-year stra-
tegic plan be considered in two 5-year periods. During
the first period, the emphasis will be on implementing
and upscaling MDA in all countries, and on stopping
MDA and initiating surveillance in areas where that is
possible.
African Development Bank
Dr Tshinko B. Ilunga, Manager of the Health Division,
African Development Bank (ADB), described the Bank’s
health programmes, which assist regional member coun-
tries in addressing health problems, implementing health
policies, and strengthening the health system. It also pro-
motes investment in other sectors that have a direct bear-
ing on health improvement (e.g., water and sanitation).
T h ef o c u so ft h eA D B ’s on-going projects and pro-
grammes include public health promotion and health sys-
tems strengthening (through formulation of health policies
and strategies; introducing reforms; and building capacity
through training and infrastructure). Within the last five
years, priority areas have included direct health investment
through the public and private sectors and investing in
environments that support health (e.g., food security,
water and sanitation, communication infrastructure).
Currently the health portfolio of the ADB is estimated
at $690 million, with 33 active investment projects in 30
regional member countries. The potential for greater
impact exists, as committed resources are not fully uti-
lized and countries tend not to request funding for
health. Dr Ilunga emphasized that all available resources
will be needed to ensure that LF elimination is funded
at an adequate level.
USAID NTD Strategy 2010-2014
Ms Angela Weaver, NTD Advisor for USAID, described
the agency’s programme to address NTDs. This pro-
gramme began in 2006, when the US Congress approved
special “earmark” funding of $15 million per year.
USAID awarded a competitive agreement to RTI to
issue competitive grants to leading technical partners;
support upscaling of MDA; help recipient countries gain
access to donated NTD drugs; contribute to lessons
learned and best practices; and develop state-of-the-art
tools for monitoring. The project started in 5 countries
(Burkina Faso, Ghana, Niger, Mali, Uganda - so-called
“fast track” countries), and has expanded through a
competitive grant process to include eight additional
countries. The focus of USAID support has been to
upscale preventive chemotherapy. USAID agrees with
the programmatic advantages of an “integrated
approach” to preventive chemotherapy. However, it is
also important to maintain a disease-specific focus;
indeed, integrated preventive chemotherapy may open
opportunities to accelerate disease-specific targets.
USAID funding for NTDs was increased to $25 mil-
lion in fiscal year (FY) 2009 and $65 million in FY 2010.
The goal of this investment is to expand integrated con-
trol of targeted NTDs to 30 countries, reducing the pre-
valence of these diseases by at least 50% among 70% of
affected populations. An estimated 1 billion treatments
Addiss and Parasites & Vectors 2010, 3:100
http://www.parasitesandvectors.com/content/3/1/100
Page 20 of 26will be provided, and it is hoped that onchocerciasis will
be eliminated in the Americas and LF will be globally
eliminated. USAID will continue to support integrated
NTD control in the 14 countries already being sup-
ported and to expand its support to an additional 16
countries by 2014.
World Bank
Professor David Molyneux read a speech prepared by
Professor Donald Bundy, currently the APOC Coordina-
tor at the World Bank. Unfortunately, Dr Bundy was
unable to attend the GAELF6. The Joint Action Forum
(JAF) of APOC recently endorsed the need to expand
integrated NTD activities including LF, and some APOC
countries are currently implementing integrated pro-
grammes. This welcome news highlights the importance
of evolving partnerships and the desire on all sides to
seek new ways of working together.
Alternative Resource Strategies for NTDs
Dr Patrick Lammie, Technical Director for the Global
Network for Neglected Tropical Diseases, highlighted
the progress of the GAELF since its inception. The
“spectacular” drug donations by Merck & Co., Inc. and
GSK, as well as early support to GAELF from the UK
Department for International Development (DFID) and
the Bill & Melinda Gates Foundation, provided the criti-
cal sparks that launched the programme.
Despite these initial major contributions, further advo-
cacy for LF alone was not terribly successful. In con-
trast, advocacy for NTDs has been remarkably effective.
The Bill & Melinda Gates Foundation provided funding
support for operational research on integrated control
of NTDs and USAID followed with an initial $100 mil-
lion in 2006. This was followed by the Obama Global
Health Initiative, which represents the culmination of
several years of concerted and targeted advocacy by
many in the NTD community. The recently-announced
USAID request for applications (RFA) would provide an
additional $450 million for control of NTDs over the
next five years. This signals a tremendous commitment
- but even this amount will not suffice. It will be critical
to mobilize additional resources if we are to finish the
job of LF elimination.
T h eG l o b a lN e t w o r kf o rN T D si sa na d v o c a c ya n d
resource mobilization initiative working with interna-
tional organizations, governments, technical agencies
and donors to enhance collaboration and coordination
in support of NTD control and elimination goals. Most
of its support comes from the Bill & Melinda Gates
Foundation. The Network works with WHO and other
partners to promote the development of regional NTD
control and elimination strategies; facilitate the develop-
ment of coordination mechanisms in support of these
strategies; and mobilize new resources to support coun-
try programmes. Because programmes and challenges
differ from region to region, regional coordination
mechanisms can build demand, improve resource flow,
and support control efforts tailored to regional needs.
Dr Lammie presented details on the Latin America
and Caribbean (LAC) Trust Fund Partnership, an exam-
ple of a successful regional effort to address NTDs. The
partnership includes the Global Network, the Inter-
American Development Bank (IDB) and the Pan Ameri-
can Health Organization (PAHO), as well as private
foundations and governments in affected countries.
Early lessons learned from LAC include the need for
strong partnerships and regional stakeholders; the essen-
tial role of governments; the advantages of advocating
for integration of NTD control and elimination efforts
with other initiatives, such as sanitation and housing;
and the necessity of having good data to successfully
mobilize resources.
Looking forward to the next 10 years, Dr Lammie
made several points. The NTD message has been very
effective, and it has provided a low-cost, high-impact
intervention for the “bottom billion.” The current global
health landscape is both complex and competitive;
donors are looking for integration and harmonisation on
a much broader platform than NTDs alone. Successful
advocacy is issue-oriented, tailored to the interests of
specific donors and partners. Nothing is more important
than morbidity management - yet efforts to address
morbidity have lagged behind. We need new partner-
ships with organizations focused on integrated morbidity
management.
Dr Lammie highlighted the need to address several
issues related to programme integration, including NTD
surveillance and vector control, the role of water and
sanitation, and completion of NTD mapping. He
encouraged the audience to share their stories of success
and their data, and he concluded with a positive mes-
sage: Advocacy works.
Future of the GAELF Partnership
Chair: Mr Andy Wright
NGDO Linkages Between LF and Other NTD Groups -
Simon Bush
Mr Simon Bush, Director of African Alliances and
Advocacy for Sightsavers International, reviewed the
role of NGDOs in NTD control. NGDOs tend to have
relatively flexible organizational structures that can
react quickly and adapt to country needs. They can
provide support to country-level or global pro-
grammes; catalyse movement towards national “owner-
ship” of programmes; bridge between the formal health
system and communities; help broker relationships
across sectors; develop effective delivery models that
can be taken to scale; and help mobilize resources and
advocacy.
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cerciasis Control was established, followed by similar
groups in support of trachoma and LF elimination.
These groups began to meet together in 2006 to develop
the NTD NGDO Network. The primary mission of this
network is to coordinate activities of members and
attempt to bridge gaps in funding. The network is not
principally a fund-raising organization, but individual
members continue to raise funds to support specific
activities.
Mr Bush encouraged all delegates at the GAELF6 to
advocate for inclusion of NTDs in the review of the
MDGs, which is currently being undertaken. A UN
review summit is scheduled for September 2010 in New
York City.
Opportunities: Advocacy and Broader Partnerships in the
Evolving Global Health Environment
Professor Molyneux noted that as late as 2000, the lar-
gest NGDOs involved in promoting eyesight and com-
batting blindness were not yet involved in LF
elimination. Since then, they have joined forces with the
GAELF - and in some cases, this has resulted in changes
to their mission statements and governance. In “teaming
up” with NTDs the LF community should consider sev-
eral issues and questions. Should the GAELF continue
as an entity - should the GAELF “brand” be maintained?
How should the GAELF engage with groups represent-
ing other NTDs, and what mechanisms exist for such
engagement? Should the GAELF focus its advocacy pri-
marily on the large and epidemiologically important
countries?
Several lessons have been learned in the short 10-year
life of the GAELF. The capacity for programme imple-
mentation is a precious resource at all levels. Advocacy
is essential. The new global health environment is com-
plex and rapidly changing. It is impossible to predict
exactly how global health will continue to develop,
although the importance of non-communicable chronic
diseases will continue to emerge. In 2015, we will enter
a “post-MDG environment,” with new challenges and
opportunities. Professor Molyneux suggested that we
keep the “NTD brand,” with LF at its core, and highlight
our successes for the purposes of advocacy.
Alternative strategies for LF elimination should be
explored, while vigorously pursuing the current strategy.
The application of alternative strategies raises many
questions, including the possible role of antibiotics, and
how they might be used in specific populations. Vector
control should be enhanced, but where, how, and by
whom?
Discussion An animated discussion followed Professor
Molyneux’s presentation. Dr Richards agreed that the
NTD “brand” is useful for advocacy, but pointed out
that disease elimination also is a cause that has
successfully attracted donors. He argued that we should
not forget the goal of LF elimination, even within the
context of NTDs. Dr Gyapong stated that use of antibio-
tics for LF elimination is a worthy topic for research,
but premature as policy. Dr John Ehrenberg, from WPR,
made the case for prioritizing a final push for LF elimi-
nation in the Pacific.
Dr Jacobson suggested three innovations for next 10
y e a r s .F i r s t ,a“buddy” or partnership programme could
be developed between countries just beginning LF elimi-
nation programmes and those with experience - espe-
cially south-to-south linkages. Second, more rapid
streamlining of research results into the field could be
facilitated by programme advisors, who could work with
country programme managers to keep them abreast of
latest research developments and provide consultation
on implementation. Finally, she suggested an “LF elimi-
nation think-tank” to consider deeply and in detail what
is needed to achieve the 2020 goal.
Conclusions and Reflections
Dr Mwele Malecela introduced the new Chair of the
GAELF Representative Contact Group (RCG), Maged
El-Setouhy, Professor of Public Health and Epidemiology
at Ain Shams University, in Cairo. She also announced
the results of the election for the Executive Group (see
below).
Dr Malecela reflected on her 4-year term as Chair of
the RCG. During this time, the RCG has worked to
establish regional platforms that focus on regional issues
and priorities in LF elimination. She emphasized that
the regionalization process will continue with integrated
NTD control programmes. She also noted that, with the
growth of the GAELF, there has been some discussion
about its future structure, and that this issue has been
referred to the next GAELF meeting.
Dr Malecela reviewed the major developments in LF
elimination over the past four years, concluding that
“the strategy does work - the glass is half-full.” Opera-
tional research has been critical in addressing chal-
lenges, and this will continue. She encouraged GAELF
members to embrace integration with NTDs and to
serve as leaders within the new initiative. Of the many
challenges that were discussed during the GAELF6,
upscaling MDA is “the big one.” Concentrated efforts
need to be made in morbidity management, with the
help of new partnerships.
Closing Ceremony
Dr Engels noted the progress made during the first 10
years of the GAELF, and agreed that the glass is half
full. But, he noted, there is no room for complacency.
Major challenges lie ahead, and strategies have been put
in place to face the challenges that will arise. Dr Engels
emphasized that teaming up with NTDs offers new
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the Korean hosts of the GAELF6, as well as Dr Malecela
and Professor Molyneux, and pledged WHO support to
Professor El-Setouhy and Dr Lammie in the months
ahead. These thanks were echoed by Dr Malecela.
Professor Molyneux thanked Dr Lee, Professor Chai
and Professor Rim for their enthusiastic support of this
meeting. He praised the strong tradition of parasitology
in Korea. He also acknowledged, with gratitude, the
work of the GAELF secretariat in Liverpool.
Dr Jong-Koo Lee expressed his gratitude and thanks
to several individuals and to all participants for a suc-
cessful meeting. For a list of persons who attended, see
additional file 1. Dr Lee thanked all those who attended
for their commitment to eliminate LF and he expressed
hope that the collaborative network represented in this
GAELF meeting had been strengthened. He pledged
Korea’s continued participation in LF elimination
through sharing its experience and providing technical
support. Dr Lee thanked all the staff from KCDC for
their work in preparing for GAELF6, and he declared
the meeting closed.
Business Session of the Representative Contact Group
(RCG)
Dr Mwele Malecela called to order the business meeting
of the RCG. Mrs Joan Fahy distributed ballots for new
officers and elections were held. Ms Angela Weaver, of
USAID filled the vacant position for donors. George-
town University (Professor Bernhard Liese) and Michi-
gan State University (Professor Charles Mackenzie) filled
the two vacancies for academic and research institu-
tions. Professor Maged El-Setouhy was elected Chair of
the RCG. Executive Group members elected were:
Patrick Lammie; Adrian Hopkins; Dominique Kyelem;
Moses Bockarie; and Frank Richards. Two ex-officio
country members, Doris Njomo (Kenya) and Rita Kus-
riastuti (Indonesia), were appointed. Dr Lammie was
elected Chair of the Executive Group.
Professor David Molyneux thanked Dr Malecela for
her leadership, time, energy, and thoroughness as Chair
of the RCG. Dr Malecela expressed her pleasure in
working with Professor Molyneux and with all the
members of the RCG and the Executive Group, saying
that it had been “a great honour and a great
experience.”
Special Session: Enhancing Disability Prevention
Implementation through Partnerships
Chair: Dr Pierre Brantus
A special session for NGDO representatives and other
interested parties was held after the close of GAELF6.
Focusing on how to develop partnerships to prevent LF
disability, the session was co-chaired by Dr Pierre
Brantus, from Handicap International, Professor Mary-
Jo Geyer, from the University of Pittsburgh, and Mr Jose
de la Cruz, from LEPRA.
Professor Geyer began by describing the “Legs to
Stand On” project in greater detail. Priorities for the
project include developing the training technology for
cross-diseases morbidity management and conducting
situation analyses in specific countries, followed by a
series of planning, implementation, and evaluation steps
(Figure 6).
Dr Brantus opened the discussion with the general
question, “How are we going to work together?” Profes-
sor Ramachandran asked about specific guidelines for
lymphoedema management. Dr Brantus indicated that
WHO guidelines have been established for a “minimum
package” that can be implemented in all LF-endemic
areas, and that they soon will be published and distribu-
ted. In some areas, additional resources and treatment
modalities, such as Ayurvedic and surgical approaches
for specific cases, may be available. These are welcome,
but they are not considered part of the minimum pack-
age for all LF-endemic areas.
Dr Manokaran Gurusamy suggested that several
multi-disease treatment centres be established to sup-
port pilot research on the epidemiology, clinical spec-
trum, and treatment for the various conditions in which
limb care is required. Professor Geyer noted that disabil-
ity prevention centres for leprosy exist in many coun-
tries, and they already are treating people with diabetic
feet. Additional diseases could readily be integrated. For
any specific geographic area, it is important to do an
initial stakeholder analysis to identify which organiza-
tions and NGDOs are available as potential partners. Dr
Brantus agreed, emphasizing the need for careful identi-
fication and cultivation of partnerships before embark-
ing on cross-diseases projects, especially if funding and
other support is to be sustainable.
Dr Paul Maurice Dogbo Pepe, from Cote d’Ivoire,
emphasized the need for better mapping of lymphoe-
dema cases, as well as other lower limb conditions, as a
necessary precursor to establishing treatment centres.
Mr Jose de la Cruz noted three types of unfamiliarity
that create barriers to integrated management of lower
limb conditions. First, there is lack of familiarity with
the clinical and social tools to address these problems,
for which guidelines are necessary. Second, there is a
lack of knowledge about the epidemiology of various
lower limb conditions in most areas. Third, there is a
lack of familiarity with other organizations that are
already addressing some of these conditions (e.g.,
NGDOs working in leprosy) that can be integrated with
LF morbidity management. He suggested that NGDOs
that are working in the field can provide WHO with a
map that indicates they are active, what they are doing,
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ful to WHO and to programme managers in developing
a coordinated approach.
Dr Leda Hernandez asked about the specific role of
the LF programme manager in morbidity management,
and considerable discussion focused on this. Dr Lisy
Rasoazanamiarana reported that, in Madagascar, the
role of the government has been to coordinate with
NGDOs to set up the programme, provide training in
morbidity management for health workers, and establish
standards for patient follow-up. The NGDOs serve as an
interface between the government and the community;
their covenant with the community enables them to
motivate community support for the programme and
ensure adequate patient follow-up. Patients with ADL
episodes are managed within the public health system.
The Ministry of Health provides training on managing a
variety of conditions of the lower limb, including dia-
betes and LF.
Dr Pepe agreed, and said that integration does not
necessarily require combining the services of several
NGDOs, all with separate disease mandates. Rather, a
single interested NGDO with expertise in one area can,
if motivated, help to address a variety of issues and dis-
eases. Especially in low-income countries, flexibility is
important.
Dr Brantus summarized the session and thanked the
participants. He noted that the publication of WHO
treatment guidelines will represent an important step
forward. He called for developing clear strategies among
interested parties, focused on integration based in part-
nership. He also acknowledged that NGDOs and Minis-
tries of Health have different roles within a partnership,
and clarity around these roles will facilitate explicit and
Figure 6 Cycle of activities proposed in the “Legs to Stand On” project.
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of lower limb care is just one expression of the impulse
toward greater integration of the health and medical sys-
tems now underway in many countries.
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